Presidents FY 1997 Science Budget Clouded By Uncertainties Of 1996

Uncertainties Of 1996 Presidential science adviser John H. Gibbons calls fiscal year 1996 a "grim year for science budgets." BACK TO BASICS: Rep. Robert Walker (R-Pa.) contends that the FY 1997 budget supports applied research at the expense of basic science. Small wonder. On March 19, President Bill Clinton submitted his FY 1997 government budget proposal to the United States Congress. Yet the FY 1996 budget, which was to take effect on Oct. 1, 1995, has yet to be agreed upon. For many scie

Written bySteven Benowitz
| 11 min read

Register for free to listen to this article
Listen with Speechify
0:00
11:00
Share

Uncertainties Of 1996 Presidential science adviser John H. Gibbons calls fiscal year 1996 a "grim year for science budgets."

Robert Walker
BACK TO BASICS: Rep. Robert Walker (R-Pa.) contends that the FY 1997 budget supports applied research at the expense of basic science.
Small wonder. On March 19, President Bill Clinton submitted his FY 1997 government budget proposal to the United States Congress. Yet the FY 1996 budget, which was to take effect on Oct. 1, 1995, has yet to be agreed upon. For many science- and technology-based federal agencies, such as the National Science Foundation, FY 1996 funding comes from a series of continuing government resolutions. Many programs languish in fiscal uncertainty.

NO WAY OUT: Rep. Vernon Ehlers (R-Mich.) argues for NSF support "NSF can't live week to week," says Rep. Vernon Ehlers (R-Mich.), a former physics professor and a member of the House Science Committee who led an unsuccessful effort ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies